KR850008336A - (s)-알파-에틸-2-옥소-1-피롤리딘 아세트 아미드의 제조방법 - Google Patents

(s)-알파-에틸-2-옥소-1-피롤리딘 아세트 아미드의 제조방법 Download PDF

Info

Publication number
KR850008336A
KR850008336A KR1019850003322A KR850003322A KR850008336A KR 850008336 A KR850008336 A KR 850008336A KR 1019850003322 A KR1019850003322 A KR 1019850003322A KR 850003322 A KR850003322 A KR 850003322A KR 850008336 A KR850008336 A KR 850008336A
Authority
KR
South Korea
Prior art keywords
oxo
alpha
ethyl
group
hal
Prior art date
Application number
KR1019850003322A
Other languages
English (en)
Other versions
KR920003819B1 (ko
Inventor
고버트 쟝 (외 2)
Original Assignee
레이몬드 두셀도르프
유 시 비 에스. 에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10560974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR850008336(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 레이몬드 두셀도르프, 유 시 비 에스. 에이 filed Critical 레이몬드 두셀도르프
Publication of KR850008336A publication Critical patent/KR850008336A/ko
Application granted granted Critical
Publication of KR920003819B1 publication Critical patent/KR920003819B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Detergent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Seasonings (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

내용 없음

Description

(S)-알파-에틸-2-옥소-1-피롤리딘 아세트 아미드의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. (S)-알파-에틸-2-옥소-1-피롤리딘 아세트 아미드.
  2. (S)-알파-에틸-2-옥소-1-피롤리딘아세트산을 계속하여 (1) Hal은 할로겐 원자를 나타내고 Z는 1 내지 4탄소원자를 갖는 알킬기를 나타내는 HalCOOZ 일반식의 알킬 할로포름에이트와 (2)암모니아와 반응시킴을 특징으로 하는 (S)-알파-에틸-2-옥소-1-피롤리딘 아세트 아미드의 제조방법.
  3. 다음 일반식 (A)의 (S)-2-아미노-부탄아미드를 불활성 용매 및 염기성 물질의 존재하에 고리화시킴을 특징으로 하는 (S)-알파-에틸-2-옥소-1-피롤리딘 아세트 아미드의 제조방법.
    X-CH2CH2-Y-NHCH(C2H5)CONH2(A)
    상기식에서 X는 XOOC-또는 HalCH2-기를 나타내며, Z는 1 내지 4탄소원자를 갖는 알킬기를 나타내며, Hal은 할로겐원자를 나타내고, Y는 -CH2- 또는 -CO- 기를 나타내며, 단, X가 ZOOC- 기를 나타낼 때 Y는 -CH2-기를 나타내고, X가 HalCH2- 기를 나타낼 때 Y는 -CO- 기를 나타내는 조건에서이다.
  4. 상기 3항에 있어, Z는 3항에 기재된 바와 같고 Hal은 할로겐 원자를 나타내는 것으로 일반식(A)의 화합물은 ZOOCCH2CH2CH2NHCH(C2H5)CONH2일반식의 알킬 (S)-4-[[1-(아미노카보닐)프로필]아미노]-부티레이트이고, (S)-2-아미노-부탄아미드를 ZOOCCH2CH2CH2Hal 일반식의 알킬 4-할로부티레이트로 축합시켜 얻음을 특징으로 하는 상기의 제조방법.
  5. 상기 3항에 있어, Hal은 할로겐원자를 나타내는데 일반식(A)의 화합물은 Hal CH2CH2CH2CONHCO(C2H5)CONH2일반식의 (S)-N-[1(아미노카보닐)프로필]-4-할로부탄아미드이고, (S)-2-아미노-부탄아미드를 Hal CH2CH2CH2COHal 일반식의 4-할로부티릴 할리드로 축합시켜 얻음을 특징으로 하는 상기의 제조방법.
  6. (S)-알파-에틸-2-옥소-1-피롤리딘 아세트 아미드의 치료 유효양과 약제학적으로 수용가능한 고체 또는 액체 희석제 또는 그것의 증량제로 구성됨을 특징으로 하는 약제 조성물.
  7. (S)-알파-에틸-2-옥소-1-피롤리딘 아세트 아미드의 유효 양을 저산소증 및 허혈증 환자에게 투여함을 특징으로 하여 그것을 필요로 하는 환자에게 항-저산소 및 항-허혈효과를 달성하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850003322A 1984-05-15 1985-05-15 (s)-알파-에틸-2-옥소-1-피롤리딘아세트아미드의 제조 방법 KR920003819B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB12357/84 1984-05-15
GB848412357A GB8412357D0 (en) 1984-05-15 1984-05-15 Pharmaceutical composition
GB84/12357 1984-05-15

Publications (2)

Publication Number Publication Date
KR850008336A true KR850008336A (ko) 1985-12-16
KR920003819B1 KR920003819B1 (ko) 1992-05-15

Family

ID=10560974

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850003322A KR920003819B1 (ko) 1984-05-15 1985-05-15 (s)-알파-에틸-2-옥소-1-피롤리딘아세트아미드의 제조 방법

Country Status (33)

Country Link
US (3) US4696943A (ko)
EP (1) EP0162036B1 (ko)
JP (1) JPH0629186B2 (ko)
KR (1) KR920003819B1 (ko)
CN (1) CN1015541B (ko)
AT (1) ATE45567T1 (ko)
AU (1) AU574465B2 (ko)
BG (2) BG50156A3 (ko)
CA (1) CA1235129A (ko)
CY (2) CY1567A (ko)
DE (3) DE10075021I1 (ko)
DK (1) DK163501C (ko)
ES (2) ES8608485A1 (ko)
FI (1) FI80673C (ko)
GB (1) GB8412357D0 (ko)
GE (1) GEP20002001B (ko)
GR (1) GR851155B (ko)
HK (1) HK52391A (ko)
IE (1) IE59950B1 (ko)
IL (1) IL75179A (ko)
LT (1) LT2584B (ko)
LU (2) LU90615I2 (ko)
LV (1) LV5233A3 (ko)
MY (2) MY101726A (ko)
NL (1) NL300028I2 (ko)
NO (2) NO164534C (ko)
PL (2) PL144346B1 (ko)
PT (1) PT80460B (ko)
SA (1) SA01210656A (ko)
SG (1) SG80090G (ko)
SU (3) SU1402260A3 (ko)
UA (1) UA6158A1 (ko)
ZA (1) ZA853635B (ko)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827389D0 (en) * 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
GB9319732D0 (en) 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US6124473A (en) * 1998-05-08 2000-09-26 Ucb, S.A. Process for preparing (s)- and (R)-α-ethyl-2-oxo-1-pyrrolidineacetamide
US6107492A (en) * 1998-05-08 2000-08-22 Ucb, S.A. Process for the preparation of levetiracetam
EA002380B1 (ru) * 1999-07-21 2002-04-25 Российский Государственный Педагогический Университет Им. А.И.Герцена Антиишемическое средство
EA002379B1 (ru) * 1999-07-21 2002-04-25 Российский Государственный Педагогический Университет Им. А.И.Герцена Средство, обладающее антиишемической, гипотензивной и антигипоксической активностью
BR0015974A (pt) 1999-12-01 2002-07-23 Ucb Sa Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) * 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
ATE397584T1 (de) * 2000-11-21 2008-06-15 Ucb Pharma Sa N-alkylierte gaba verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE60138733D1 (de) 2000-12-28 2009-06-25 Hamilton Pharmaceuticals Inc Arzneimittel zur behandlung und vermeidung neurogener schmerzen
AU2002245486B2 (en) * 2001-02-23 2006-11-16 Ucb Pharma, S.A. Treatment of tics, tremors and related disorders
DE60229267D1 (de) 2001-08-10 2008-11-20 Ucb Pharma Sa Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen
DE60218193T2 (de) * 2001-10-08 2007-11-22 Ucb S.A. Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
AU2003242538A1 (en) * 2002-05-14 2003-11-11 Ucb, S.A. Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
EP1517893A2 (en) * 2003-02-03 2005-03-30 Teva Pharmaceutical Industries Limited Process for producing levetiracetam
ES2214147B1 (es) * 2003-02-28 2005-10-01 Farma-Lepori S.A. Procedimiento de obtencion de un agente antiepileptico.
AU2003217438A1 (en) * 2003-03-18 2004-10-11 Hetero Drugs Limited Novel crystalline forms of levetiracetam
WO2005023763A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Process for the preparation of pure levetiracetam
EP1667967B1 (en) * 2003-09-24 2012-08-01 UCB Pharma, S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives
ZA200604410B (en) 2003-12-02 2008-09-25 Ucb Sa Imidazole derivatives, processes for preparing them and their uses
US7531673B2 (en) 2004-02-18 2009-05-12 Dr. Reddy's Laboratories Limited Preparation of amino acid amides
CA2488325C (en) * 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
CN101111245A (zh) * 2005-01-27 2008-01-23 阿雷姆贝克有限公司 左乙拉西坦延长释放制剂
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
WO2006088864A1 (en) * 2005-02-16 2006-08-24 Elan Pharma International Limited Controlled release compositions comprising levetiracetam
WO2006090265A2 (en) * 2005-02-28 2006-08-31 Ranbaxy Laboratories Limited Processes for the preparation of levetiracetam, its intermediate and the use of levetiracetam in pharmaceutical compositions
WO2006095362A1 (en) * 2005-03-10 2006-09-14 Rubamin Limited Process for preparing levetiracetam
JP2008534522A (ja) 2005-03-30 2008-08-28 ジェンファーム インク 医薬組成物のための複合ステップ製造方法
WO2006103696A2 (en) * 2005-04-01 2006-10-05 Rubamin Laboratories Limited Process for preparing levetiracetam and racemization of (r)- and (s)-2-amino butynamide and the corresponding acid derivatives
JP2008542322A (ja) 2005-06-01 2008-11-27 ユセベ ファルマ ソシエテ アノニム ２−オキソ−１−ピロリジン誘導体
NZ554157A (en) * 2005-07-26 2010-12-24 Glaxo Smithkline Trading Services Ltd Pharmaceutical compositions comprising levetiracetam and process for their preparation
US8338621B2 (en) 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
JP2009524658A (ja) * 2006-01-24 2009-07-02 テバ ファーマシューティカル インダストリーズ リミティド レベチラセタム製剤、及びそれらの製造方法
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
CN101511786A (zh) * 2006-07-25 2009-08-19 Zach系统股份公司 制备左乙拉西坦的方法
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
CN101130504B (zh) * 2006-08-25 2010-07-28 苏州雅本化学股份有限公司 经合成、拆分与消旋化制备手性药物左乙拉西坦中间体(s)-(+)-2-氨基丁酰胺盐酸盐的方法
EP1932922A1 (de) * 2006-12-13 2008-06-18 Desitin Arzneimittel GmbH Schnelltest zum Nachweis von DNA-Sequenzen
WO2008077035A2 (en) * 2006-12-18 2008-06-26 Dr. Reddy's Laboratories Ltd. Processes for the preparation of levetiracetam
CN101333180B (zh) * 2007-06-29 2011-05-18 浙江华海药业股份有限公司 一种制备左乙拉西坦中间体的方法
US20090082422A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levetiracetam
WO2009050735A1 (en) * 2007-10-15 2009-04-23 Lupin Limited A novel polymorph of levetiracetam and a process for its preparation
US20090263481A1 (en) * 2008-04-17 2009-10-22 Atul Vishvanath Patil Levetiracetam formulations
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
EP2147911A1 (en) 2008-07-24 2010-01-27 ZaCh System S.p.A. Process for the preparation of levetiracetam
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
JP5917148B2 (ja) 2008-10-16 2016-05-11 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ 認知機能を改善するための方法および組成物
EP2179725A1 (en) 2008-10-23 2010-04-28 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising levetiracetam
JP5753785B2 (ja) * 2008-11-07 2015-07-22 ノバベイ・ファーマシューティカルズ・インコーポレイテッドＮｏｖａｂａｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 抗菌オキサゾリジノン、ヒダントインおよびイミダゾリジノン組成物
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
US8785661B2 (en) 2009-05-13 2014-07-22 Nektar Therapeutics Oligome-containing pyrrolidine compounds
CN101885696A (zh) * 2009-05-14 2010-11-17 上海华理生物医药有限公司 一种合成高纯度左乙拉西坦的方法
EP2461808A2 (en) 2009-08-07 2012-06-13 UCB Pharma S.A. Methods for enhancing the cognitive function
EP2298290A1 (en) 2009-09-16 2011-03-23 LEK Pharmaceuticals d.d. Controlled release composition comprising levetiracetam
US7939676B2 (en) * 2009-09-17 2011-05-10 Zach System S.P.A. Process for the preparation of levetiracetam
BR112012009310B8 (pt) 2009-10-23 2021-05-25 Ucb Biopharma Sprl composto derivados de 2-oxo-1-pirrolidinil imidazotiadiazol, uso dos mesmos e composição farmacêutica compreendendo os mesmos
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
US9187774B2 (en) 2010-02-26 2015-11-17 The Regents Of The University Of California Compositions and methods for the production of L-homoalanine
WO2011136751A2 (en) 2010-04-26 2011-11-03 Mahmut Bilgic Water soluble pharmaceutical composition
US9333175B2 (en) 2010-06-16 2016-05-10 Mylan Inc. Controlled release levetiracetam formulations and methods for producing the same
EP2492354A1 (en) 2011-02-23 2012-08-29 Institut National De La Recherche Agronomique (INRA) Method for identifying compounds useful in the treatment of photosensitive reflex epilepsy
DK2699581T3 (en) 2011-04-18 2016-01-11 Ucb Biopharma Sprl 2-oxo-1-IMIDAZOLIDINYLIMIDAZOTHIADIAZOLDERIVATIVER
EP2524910A1 (en) 2011-05-17 2012-11-21 DSM IP Assets B.V. Process for the resolution of aminobutyramide
CN102382027B (zh) * 2011-09-20 2013-11-13 浙江江北药业有限公司 一种左乙拉西坦的制备方法
CN102617436B (zh) * 2012-03-20 2014-02-12 浙江洪波化工有限公司 2-(2-氧代吡咯烷基）丁酰胺的制备方法
CN102633675A (zh) * 2012-04-10 2012-08-15 南京大学 一种dl-2-氨基丁酰胺制备方法
CN102675181B (zh) * 2012-06-07 2013-11-20 北京师宏药物研制中心 一种左乙拉西坦的制备方法
CN102702063B (zh) * 2012-06-15 2013-09-04 孙威 一种左乙拉西坦制备方法
WO2014012563A1 (en) 2012-07-20 2014-01-23 Ucb Pharma, S.A. Compounds for enhancing the cognitive function
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN103012190B (zh) * 2012-12-05 2015-03-18 江苏拜克新材料有限公司 一种s-2-氨基丁酰胺盐酸盐的合成方法
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
CA2906029C (en) 2013-03-15 2017-09-05 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
EA201891617A3 (ru) 2014-01-21 2019-04-30 Янссен Фармацевтика Нв Комбинации, содержащие положительные аллостерические модуляторы или ортостерические агонисты метаботропного глутаматергического рецептора 2 подтипа, и их применение
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
CN103910649A (zh) * 2014-04-29 2014-07-09 苏州天马精细化学品股份有限公司 一种左乙拉西坦中间体（s）-n-[1-(氨基羰基)丙基]-4-氯代丁酰胺的合成方法
CN103922988A (zh) * 2014-04-29 2014-07-16 苏州天马精细化学品股份有限公司 一种左乙拉西坦粗品的纯化方法
CN104860863B (zh) * 2015-04-10 2017-06-20 惠州信立泰药业有限公司 左乙拉西坦和含其的药物组合物
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
US10973783B2 (en) 2015-12-30 2021-04-13 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
CN106432032B (zh) * 2016-09-14 2019-07-12 苏州天马药业有限公司 一种左乙拉西坦的制备方法
CN106591179B (zh) * 2016-12-05 2018-07-03 长兴制药股份有限公司 甲基包囊菌及其在选择性拆分制备(S)-α-乙基-2-氧-1-吡咯烷乙酸盐上的应用
CN110072521B (zh) 2016-12-16 2022-11-29 爱杜西亚药品有限公司 包含t型钙通道阻断剂的药物组合
CN108503610B (zh) 2017-02-24 2019-09-13 北京艾百诺医药股份有限公司 一种光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的制备方法
CN107337628B (zh) * 2017-08-10 2022-02-08 浙江华海药业股份有限公司 一种制备左乙拉西坦的方法
TWI826531B (zh) 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
CN110003074A (zh) 2019-04-23 2019-07-12 浙江华海药业股份有限公司 一种左乙拉西坦中间体的制备方法
TW202114655A (zh) 2019-08-14 2021-04-16 瑞士商辛鐵堤卡公司 左乙拉西坦(levetiracetam)之鞘內投藥
US11384050B1 (en) 2021-02-03 2022-07-12 Vitaworks Ip, Llc Method for preparing levetiracetam and intermediates thereof
JP2024508052A (ja) 2021-02-26 2024-02-21 シンデシ セラピューティクス ソシエテ アノニム 認知障害の治療のための化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1309692A (en) * 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
GB1583871A (en) * 1976-10-19 1981-02-04 Ucb Sa Anti-aggregants
FR2418790A1 (fr) * 1978-03-02 1979-09-28 Philagro Sa Nouveaux derives de pyrrolidinone-2 et compositions herbicides les contenant
GB8412358D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition

Also Published As

Publication number Publication date
MY101725A (en) 1992-01-17
NL300028I1 (nl) 2001-02-01
IE59950B1 (en) 1994-05-04
GB8412357D0 (en) 1984-06-20
DE10199005I1 (de) 2001-07-12
NL300028I2 (nl) 2001-06-01
US4837223A (en) 1989-06-06
CY1567A (en) 1991-12-20
LU90615I2 (fr) 2000-10-02
SU1428195A3 (ru) 1988-09-30
ES8704893A1 (es) 1987-04-16
FI851875L (fi) 1985-11-16
BG47497A3 (en) 1990-07-16
NO164534B (no) 1990-07-09
SG80090G (en) 1990-11-23
BG50156A3 (en) 1992-05-15
SU1430392A1 (ru) 1988-10-15
LV5233A3 (lv) 1993-10-10
DE10075021I1 (de) 2000-10-19
DE3572348D1 (de) 1989-09-21
CY2004007I2 (el) 2009-11-04
GR851155B (ko) 1985-11-25
EP0162036B1 (fr) 1989-08-16
DK163501B (da) 1992-03-09
CY2004007I1 (el) 2009-11-04
DE10199005I2 (de) 2002-03-14
ZA853635B (en) 1985-12-24
KR920003819B1 (ko) 1992-05-15
AU4253085A (en) 1986-11-20
ES8704893B9 (es) 2012-02-07
IL75179A (en) 1988-05-31
FI80673C (fi) 1990-07-10
NO164534C (no) 1990-10-17
IE851193L (en) 1985-11-15
US4696943A (en) 1987-09-29
JPS60252461A (ja) 1985-12-13
NO2001008I2 (no) 2005-05-30
DK163501C (da) 1992-07-27
HK52391A (en) 1991-07-19
PL253374A1 (en) 1986-05-06
PL144346B1 (en) 1988-05-31
PT80460A (fr) 1985-06-01
CN85105301A (zh) 1987-01-14
PT80460B (pt) 1987-08-19
MY101726A (en) 1992-01-17
ES543124A0 (es) 1986-06-16
AU574465B2 (en) 1988-07-07
CN1015541B (zh) 1992-02-19
US4943639A (en) 1990-07-24
EP0162036A1 (fr) 1985-11-21
SU1402260A3 (ru) 1988-06-07
IL75179A0 (en) 1985-09-29
DK212985D0 (da) 1985-05-14
GEP20002001B (en) 2000-03-10
SA01210656A (ar) 2005-12-03
CA1235129A (en) 1988-04-12
PL147386B1 (en) 1989-05-31
FI80673B (fi) 1990-03-30
LT2584B (lt) 1994-03-25
JPH0629186B2 (ja) 1994-04-20
ATE45567T1 (de) 1989-09-15
ES8608485A1 (es) 1986-06-16
NO851933L (no) 1985-11-18
PL257385A1 (en) 1986-10-07
FI851875A0 (fi) 1985-05-13
LU90682I2 (fr) 2001-01-30
UA6158A1 (uk) 1994-12-29
DK212985A (da) 1985-11-16

Similar Documents

Publication Publication Date Title
KR850008336A (ko) (s)-알파-에틸-2-옥소-1-피롤리딘 아세트 아미드의 제조방법
ATE25974T1 (de) Acyl-substituierte derivate von 1,2,3,4tetrahydroisochinolin-3-carboxysaeuren, ihre salze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung.
KR860009007A (ko) 피페리딜리덴 디하이드로-디벤조[a,d]-사이클로헵텐의 제조방법
ES8506677A1 (es) Un procedimiento para la preparacion de nuevos derivados de 8-cloro71,5-benzotiazepina.
IE811830L (en) Indoles.
ES8503667A1 (es) Un procedimiento para la preparacion de nuevos derivados de 2-oxo-imidazolina.
CA2018563A1 (en) N-heteroaryl-purin-6-amines, a process for their preparation and their use as medicaments
KR860008973A (ko) 2-피롤리돈 유도체
GB1528723A (en) 1-nitro-9-n-substituted aminoalkylamino-acridines their salts and a method of preparing same
CA2052912A1 (en) Process for producing optically active amines
KR920000762A (ko) 아미노산 유도체
FI834800A (fi) Foerfarande foer framstaellning av dialkylaminoalkoxibensylalkohol-derivat.
ES465537A1 (es) Un procedimiento para la preparacion de un alcohol-x-(3,4- dimetoxifenetilaminometil)-2-alcoxibencilico racemico u op- ticamente activo
KR880006239A (ko) 기라제 억제제, 그의 제조방법 및 용도
KR880013929A (ko) 신규 5-메톡시 알킬 암노늄 테트라히드로푸란 및 테트라히드로티오펜
TW339325B (en) Novel azepane derivatives, process for the preparation thereof and pharmaceutical composition containing the same
KR850008337A (ko) (s)-알파-에틸-2-옥소-1-피롤리딘아세트 아미드의 제조방법
PL244610A1 (en) Process for preparing novel derivatives of benzazepine
KR850005435A (ko) 3-알콕시-2-(n-피롤리디노)-n-피리미디닐-또는 n-피라지닐 프로필아민의 제조방법
ES8201541A1 (es) Un procedimiento para la preparacion de nuevas guanilamidi- nas
KR840008012A (ko) 아미노에틸-피리딘 및 -피라진유도체의 제조방법
KR830005151A (ko) 헤테로 시클릭 화합물의 제조 방법 및 이것의 조성물
KR850008665A (ko) 시클로알칸-인덴-카르복시미드아미드 유도체의 제조방법
SE8206230D0 (sv) Novel cyclic imines, their preparation and pharmaceutical compositions containing the same
KR920004377A (ko) 피리딘카복실산 아미드 유도체 및 이를 함유하는 약제학적 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040323

Year of fee payment: 13

EXPY Expiration of term